News
Novo Nordisk (NVO) (OTCPK:NONOF) appears to have forced its CEO, Lars Fruergaard Jørgensen, to resign as the Danish pharma ...
Evan David Seigerman, BMO Capital Markets head of healthcare research, joins CNBC's 'Money Movers' to discuss reactions to ...
Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...
It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through ...
Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...
Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s ...
Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...
Meanwhile, Eli Lilly's Zepbound injection has gained traction, prompting both firms to race toward more convenient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback